{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T08:08:58Z","timestamp":1792483738742,"version":"4.5.0"},"reference-count":28,"publisher":"Oceanside Publications Inc.","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2026,7,1]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    Reliable biomarkers that predict delayed treatment-free remission with omalizumab in chronic spontaneous urticaria (CSU) remain unclear.\n                    <jats:bold>Objective:<\/jats:bold>\n                    The objective was to identify independent predictors of delayed treatment-free remission with\n omalizumab by comparing patients who achieved treatment-free remission with \u2264 12 doses with those who required &gt; 12 doses.\n                    <jats:bold>Methods:<\/jats:bold>\n                    This single-center retrospective study included 163 adult patients with antihistamine-refractory CSU who were treated with omalizumab\n (300 mg every 4 weeks) between January 2018 and October 2025. Treatment discontinuation was considered only after at least six consecutive doses and complete disease control, defined as a urticaria control test (UCT) score of 16 with no wheals or angioedema. Treatment-free remission was defined\n as a symptom-free period of at least 6 months without pharmacotherapy after discontinuation. Patients were classified as having early remission (\u226412 doses) or delayed remission (&gt;12 doses). Demographic, clinical, and laboratory variables were compared, and multivariable logistic regression\n was performed.\n                    <jats:bold>Results:<\/jats:bold>\n                    Of the 163 patients (median age, 41 years; 60.1% women), 99 (60.7%) had delayed remission and 64 (39.3%) had early remission. Delayed remission was associated with a higher prevalence of autoimmune disease in the delayed remission group than in the\n early remission group (27.3% versus 12.5%; p = 0.025) longer symptom duration before omalizumab initiation (p\u2009&lt;\u20090.001), and higher baseline total immunoglobulin E (IgE) levels (p\u2009&lt;\u20090.001). In multivariable analysis, longer pretreatment symptom duration (odds\n ratio [OR] 1.023 [95% confidence interval {CI}, 1.009\u20101.038]; p\u2009=\u20090.002) and autoimmune disease (OR 2.984 [95% CI, 1.130\u20107.882]; p\u2009=\u20090.027) independently predicted delayed remission, whereas the total IgE value did not (p\u2009=\u20090.070).\n                    <jats:bold>Conclusion:<\/jats:bold>\n                    Longer pretreatment symptom duration and coexisting autoimmune disease were the strongest independent predictors of delayed treatment-free remission with omalizumab in CSU.\n                  <\/jats:p>","DOI":"10.2500\/aap.2026.47.260037","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T04:30:30Z","timestamp":1782361830000},"page":"282-290","source":"Crossref","is-referenced-by-count":2,"title":["Predictors of delayed treatment-free remission with omalizumab in chronic spontaneous urticaria"],"prefix":"10.2500","volume":"47","author":[{"given":"Sukran","family":"Aslan Savas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatih","family":"Colkesen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Emin","family":"Gerek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ummugulsum Yilmaz","family":"Ergun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emrah","family":"Harman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Secim","family":"Kolak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ferhat","family":"Sagun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ismail","family":"Yigitdol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevket","family":"Arslan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/all.15090","article-title":"The international EAACI\/GA2LEN\/EuroGuiDerm\/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria","volume":"77","author":"Zuberbier","year":"2022","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jaad.2019.02.064","article-title":"Prevalence estimates for chronic urticaria in the United States: a sex- and age-adjusted population analysis","volume":"81","author":"Wertenteil","year":"2019","journal-title":"J Am Acad Dermatol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/j.1398-9995.2010.02496.x","article-title":"Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report","volume":"66","author":"Maurer","year":"2011","journal-title":"Allergy"},{"key":"B4","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/j.jaci.2022.04.010","article-title":"Autoimmune chronic spontaneous urticaria","volume":"149","author":"Kolkhir","year":"2022","journal-title":"J Allergy Clin Immunol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.jaci.2017.10.035","article-title":"IL-24 is a common and specific autoantigen of IgE in patients with chronic spontaneous urticaria","volume":"142","author":"Schmetzer","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"B6","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jaip.2018.04.013","article-title":"Chronic spontaneous urticaria: the devil's itch","volume":"6","author":"Saini","year":"2018","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B7","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s13555-023-01040-9","article-title":"Omalizumab for patients with chronic spontaneous urticaria: a narrative review of current status","volume":"13","author":"Casale","year":"2023","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B8","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1016\/j.jaip.2025.07.021","article-title":"Management of chronic spontaneous urticaria made practical: what every clinician should know","volume":"13","author":"Kocat\u00fcrk","year":"2025","journal-title":"J Allergy Clin Immunol Pract"},{"key":"B9","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.jaci.2024.11.039","article-title":"Chronic spontaneous urticaria remission definition and therapy stepping down: World Allergy Organization position paper","volume":"155","author":"S\u00e1nchez","year":"2025","journal-title":"J Allergy Clin Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"38","DOI":"10.5021\/ad.2020.32.1.38","article-title":"Natural history of chronic urticaria in Korea","volume":"32","author":"Chung","year":"2020","journal-title":"Ann Dermatol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1159\/000526205","article-title":"Comparison of the patients with chronic urticaria who responded and did not respond to omalizumab treatment: a single-center retrospective study","volume":"183","author":"Cakmak","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"100386","DOI":"10.1016\/j.jacig.2024.100386","article-title":"Utility of serum biomarkers in real-world practice for predicting response to omalizumab therapy in patients with chronic spontaneous urticaria","volume":"4","author":"Cain","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B13","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1111\/all.14033","article-title":"Antinuclear antibodies are common and linked to poor response to omalizumab treatment in patients with CSU","volume":"75","author":"Erta\u015f","year":"2020","journal-title":"Allergy"},{"key":"B14","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.aller.2016.04.011","article-title":"The predictive factors for remission of chronic spontaneous urticaria in childhood: outcome from a prospective study","volume":"44","author":"Eser","year":"2016","journal-title":"Allergol Immunopathol (Madr)"},{"key":"B15","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1097\/CM9.0000000000002172","article-title":"Epidemiology of urticaria in China: a population-based study","volume":"135","author":"Li","year":"2022","journal-title":"Chin Med J (Engl)"},{"key":"B16","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s13555-021-00641-6","article-title":"Clinical remission of chronic spontaneous urticaria (CSU): a targeted literature review","volume":"12","author":"Balp","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B17","doi-asserted-by":"crossref","first-page":"2747","DOI":"10.1007\/s13555-022-00827-6","article-title":"Predicting clinical remission of chronic urticaria using random survival forests: machine learning applied to real-world data","volume":"12","author":"Pivneva","year":"2022","journal-title":"Dermatol Ther (Heidelb)"},{"key":"B18","doi-asserted-by":"crossref","first-page":"100245","DOI":"10.1016\/j.jacig.2024.100245","article-title":"Predicting responses to omalizumab in antihistamine-refractory chronic urticaria: a real-world longitudinal study","volume":"3","author":"Lee","year":"2024","journal-title":"J Allergy Clin Immunol Glob"},{"key":"B19","doi-asserted-by":"crossref","first-page":"3077","DOI":"10.1111\/all.70052","article-title":"Microenvironment-driven mast cell plasticity: insights from cytokine-activated gene signatures in skin and respiratory diseases","volume":"80","author":"Tontini","year":"2025","journal-title":"Allergy"},{"key":"B20","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.jaci.2012.01.043","article-title":"Chronic urticaria and autoimmunity: associations found in a large population study","volume":"129","author":"Confino-Cohen","year":"2012","journal-title":"J Allergy Clin Immunol"},{"key":"B21","doi-asserted-by":"crossref","first-page":"9856843","DOI":"10.1155\/2018\/9856843","article-title":"Thyroid autoimmunity and autoimmunity in chronic spontaneous urticaria linked to disease severity, therapeutic response, and time to remission in patients with chronic spontaneous urticaria","volume":"2018","author":"Chanprapaph","year":"2018","journal-title":"Biomed Res Int"},{"key":"B22","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3390\/diagnostics15050608","article-title":"Autoimmune thyroid diseases in chronic spontaneous urticaria: the role of hormones, anti-thyroid antibodies, and ultrasound","volume":"15","author":"Golu\u0161in","year":"2025","journal-title":"Diagnostics (Basel)"},{"key":"B23","doi-asserted-by":"crossref","first-page":"1451296","DOI":"10.3389\/falgy.2024.1451296","article-title":"IgE as a predictor to omalizumab response in patients with chronic spontaneous urticaria","volume":"5","author":"Ensina","year":"2025","journal-title":"Front Allergy"},{"key":"B24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s13223-020-00461-x","article-title":"Presence of positive skin prick tests to inhalant allergens and markers of T2 inflammation in subjects with chronic spontaneous urticaria (CSU): a systematic literature review","volume":"16","author":"Wong","year":"2020","journal-title":"Allergy Asthma Clin Immunol"},{"key":"B25","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1159\/000346896","article-title":"Parameters associated with chronic spontaneous urticaria duration and severity: a systematic review","volume":"161","author":"Rabelo-Filardi","year":"2013","journal-title":"Int Arch Allergy Immunol"},{"key":"B26","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.2500\/aap.2021.42.200088","article-title":"Hematologic parameters as biomarkers for antihistamine and omalizumab resistance in chronic spontaneous urticaria","volume":"42","author":"Magen","year":"2021","journal-title":"Allergy Asthma Proc"},{"key":"B27","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1111\/jdv.14221","article-title":"Factors linked to disease severity and time to remission in patients with chronic spontaneous urticaria","volume":"31","author":"S\u00e1nchez-Borges","year":"2017","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"B28","doi-asserted-by":"crossref","first-page":"7468453","DOI":"10.1155\/2022\/7468453","article-title":"Do antinuclear antibodies influence the clinical features of chronic spontaneous urticaria?: A retrospective cohort study","volume":"2022","author":"Arunkajohnsak","year":"2022","journal-title":"Biomed Res Int"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2026\/00000047\/00000004\/art00010","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T04:37:50Z","timestamp":1782880670000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2026.47.260037"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,1]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7,1]]}},"alternative-id":["1088-5412(20260701)47:4L.282;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2026.47.260037","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,1]]}}}